While the ERα-agonist PPT had a minimal effect in the reversal of fibrosis in the heart and was able to decrease the transcript levels of collagen I and TGF-β1, it was not able to significantly decrease the elevated transcript levels of collagen III, LOX and fibrosin I observed in HF. The gene discussed is LOX; the disease is hydrops fetalis.